Insulin-Like Growth Factor-1 Supplementation Promotes Brain Maturation in Preterm Pigs

Very preterm infants show low levels of insulin-like growth factor-1 (IGF-1), which is associated with postnatal growth restriction and poor neurologic outcomes. It remains unknown whether supplemental IGF-1 may stimulate neurodevelopment in preterm neonates. Using cesarean-delivered preterm pigs as...

Full description

Saved in:
Bibliographic Details
Published ineNeuro Vol. 10; no. 4; p. ENEURO.0430-22.2023
Main Authors Christiansen, Line I, Holmqvist, Bo, Pan, Xiaoyu, Holgersen, Kristine, Lindholm, Sandy E H, Henriksen, Nicole L, Burrin, Douglas G, Ley, David, Thymann, Thomas, Sangild, Per Torp, Pankratova, Stanislava
Format Journal Article
LanguageEnglish
Published United States Society for Neuroscience 01.04.2023
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Very preterm infants show low levels of insulin-like growth factor-1 (IGF-1), which is associated with postnatal growth restriction and poor neurologic outcomes. It remains unknown whether supplemental IGF-1 may stimulate neurodevelopment in preterm neonates. Using cesarean-delivered preterm pigs as a model of preterm infants, we investigated the effects of supplemental IGF-1 on motor function and on regional and cellular brain development. Pigs were treated with 2.25 mg/kg/d recombinant human IGF-1/IGF binding protein-3 complex from birth until day 5 or 9 before the collection of brain samples for quantitative immunohistochemistry (IHC), RNA sequencing, and quantitative PCR analyses. Brain protein synthesis was measured using labeling with [2H5] phenylalanine. We showed that the IGF-1 receptor was widely distributed in the brain and largely coexisted with immature neurons. Region-specific quantification of IHC labeling showed that IGF-1 treatment promoted neuronal differentiation, increased subcortical myelination, and attenuated synaptogenesis in a region-dependent and time-dependent manner. The expression levels of genes involved in neuronal and oligodendrocyte maturation, and angiogenic and transport functions were altered, reflecting enhanced brain maturation in response to IGF-1 treatment. Cerebellar protein synthesis was increased by 19% at day 5 and 14% at day 9 after IGF-1 treatment. Treatment had no effect on Iba1 microglia or regional brain weights and did not affect motor development or the expression of genes related to IGF-1 signaling. In conclusion, the data show that supplemental IGF-1 promotes brain maturation in newborn preterm pigs. The results provide further support for IGF-1 supplementation therapy in the early postnatal period in preterm infants.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
The University of Copenhagen represented by authors K.H., T.T., P.T.S., and S.P., and the company Oak Hill Bio have filed a patent application directed to use of rhIGF-1 for preterm infants. The remaining authors report no conflict of interest.
Author contributions: D.L., T.T., P.T.S., and S.P. designed research; L.I.C., B.H., X.P., K.H., S.E.H.L., N.L.H., D.G.B., D.L., T.T., and S.P. performed research; L.I.C., B.H., X.P., D.G.B., and D.L. analyzed data; L.I.C., D.G.B., P.T.S., and S.P. wrote the paper.
The University of Copenhagen received funding from Takeda Pharmaceutical Company. This funder was not involved in the study execution, collection, analysis, interpretation of data, the drafting of this article, or the decision to submit it for publication.
ISSN:2373-2822
2373-2822
DOI:10.1523/ENEURO.0430-22.2023